AIDS.GOV | SERVICE LOCATOR | SEARCH

BLOG.AIDS.GOV

MENU

Research

USG @ AIDS 2012: How to Talk About a “Cure”

blog.aids.gov

In an interview with AIDS.gov Director Miguel Gomez, Dr. Carl Dieffenbach discussed how to talk about “a cure” for HIV, and how talk of a cure is different from talk of an “AIDS-free generation.” Dr. Dieffenbach is Director of the Division of AIDS at the National Institute of Allergy and Infectious Diseases (NIAID). According to…

25 Years of HIV/AIDS Training has Transformed the Research Landscape

Dr. Ken Bridbord

Dr. Bridbord was a co-chair of the International AIDS Conference in 1987. Conversations I had with colleagues in June of 1987, during the last AIDS meeting held here in Washington, inspired me to develop a program that would create HIV/AIDS research expertise in the regions where the need was greatest. While we knew much less…

Answering the Call to Action with Science

Dr. Roger Glass

Twenty-five years ago, we were horrified to see the toll HIV/AIDS was taking in the developing world. Not only did it wipe out nearly a generation of adults in sub-Saharan Africa, it also killed countless children and left many more orphans. After several decades of improving indicators of health, life expectancy in sub-Saharan Africa began…

USG at AIDS 2012: Video with Dr. Anthony Fauci

faucikoh

Dr. Howard Koh, Assistant Secretary for Health at HHS, sat down with Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases at NIH to discuss his speech at the opening plenary of AIDS 2012 and his 31 years as a physician and leader in HIV/AIDS scientific research. Having participated in International…

NIH Leadership at the XIX International AIDS Conference

Dr. Jack Whitescarver

The hosting of the XIX International AIDS Conference in our nation’s capital, Washington, DC, is a tremendous opportunity to reflect on how AIDS has affected the United States, and how the United States has worked to reduce the impact of the epidemic in the U.S. and around the world. The first cases of what we…

FDA approves first drug for reducing the risk of sexually acquired HIV infection

blog.aids.gov

Today (July 16, 2012), the U.S. Food and Drug Administration approved Truvada (emtricitabine/tenofovir disoproxil fumarate), the first drug approved to reduce the risk of HIV infection in uninfected individuals who are at high risk of HIV infection and who may engage in sexual activity with HIV-infected partners. Truvada, taken daily, is to be used for…

Increasing HIV Testing, Including Rapid Testing, in Substance Abuse Treatment Programs

Dr. Valdiserri

Although the U.S. has made progress in reducing the number of new HIV infections among injection drug users and their sexual partners, CDC estimates that injection drug users represented 9% of new HIV infections in 2009 and 17% of those living with HIV in 2008.  Since the U.S. HIV/AIDS epidemic began, more than 175,000 injection…

Turning the Tide Together: Looking To the XIX International AIDS Conference in Washington, D.C.

Anthony Fauci

Next month, the International AIDS Conference returns to Washington, D.C., where it was last held in 1987. One of us (ASF) had the privilege of speaking at the 1987 conference, and will do so again this year. At the Washington conference 25 years ago, the mood was somber. The HIV/AIDS pandemic was expanding rapidly. Although…